The use of continuous glucose monitoring has created new glucose metrics for both people with diabetes and healthcare professionals to incorporate into diabetes management. While A1C is an average, time in range (TIR) captures when glucose is in the target range (70 mg/dL-180 mg/dL for most individuals), as well as when glucose is above range and below range, providing critical information for treatment decisions as well as health behavior changes. Time in range discussions can lead to more productive diabetes conversations when incorporating strength-based language principles and can lead to discovery learning.
This webinar will review CGM metrics and key principles for educating people with diabetes about TIR goals and opportunities to increase time in range. We’ll share specific features of real-time CGM that may help people move towards more TIR and less time below range. Finally, we’ll present a case study using TIR metrics to incorporate shared decision-making to modify the treatment plan.
This webinar is sponsored by Dexcom.
- Describe the Consensus Guidelines for time in range measurement and goals for most people with type 1 and type 2 diabetes.
- List 3 features of real-time continuous glucose monitoring that may help people increase time in range.
- Compare the benefits of time in range and CGM metrics in making treatment decisions compared to A1C and blood glucose meter data.
1. Overview of current model of care
- Challenges with A1C and blood glucose monitoring
- Need for metrics beyond A1C
2. International Consensus guidelines on time in range report
- CGM metrics
- Time in range goals
- Time in range associated with A1C levels
3. Strength-based language and time in range discussions
- Discovery learning
- More green, less red
- Flat, narrow and in-range
4. Dexcom G6 App and CLARITY app features that may increase time in range
- Dexcom G6 Urgent Low Soon alert
- CLARITY push notifications
- Follow app
5. Case study
This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, nurse practitioners, clinical nurse specialists, PAs, physicians, and other health care providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.
This webinar is FREE for ADCES members and non-members.
Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
Deborah Greenwood, PhD, RN, BC-ADM, CDCES, FADCES
Jami Klein, RN, BSN, CDCES
Deborah Greenwood is a nurse, certified diabetes care and education specialist and researcher. She is an Adjunct, Assistant Professor at UT Health San Antonio School of Nursing and co-authors a blog on the use of incorporating solution-focused practices in diabetes care and education. Deborah was the 2015 President of ADCES.
Jami Klein is a nurse and certified diabetes care and education specialist who is passionate about education and technology to improve the lives of those living with diabetes. She has lived with type 1 diabetes since 1988 and had various roles in the diabetes field for most of her career.
You can find the link to the Dexcom G6 User Guide here
Dexcom G6 Statements
Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings. precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you're taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
The web-based Dexcom CLARITY software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.
Dexcom. Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
Dexcom, Inc. I 6340 Sequence Drive I San Diego, CA 92121
Technical Support: 1-877-339-2664 I www.dexcom.com
©2019 Dexcom, Inc. All rights reserved.
Test Your Computer
To ensure that your participation is
successful, please test your system as soon as possible so if you do have
technical challenges, you will have time to get them sorted out. Click here to test your
While you can participate with a 56K
dialup internet connection, it is recommended that you have a high-speed
broadband (or better) internet connection. Please be sure you close as many
open programs on your system as possible. Click here for operating system